Platform for breakthrough mental health research and treatment
Osmind is the premier platform for clinicians and researchers advancing new life-saving mental health treatments. Today, mental health disorders are one of the leading causes of death worldwide, especially among young adults, and are tied to shortening lifespans. While there have been developments in new psychiatric medications since the first FDA approval in 1954, today there is a growing movement among clinicians, patients, and researchers who are recognizing the need to accelerate new science.
The Osmind treatment platform is the first and only solution that solves specific challenges faced by neuropsychiatric clinics, spanning general psychiatry and interventional psychiatry (transcranial magnetic stimulation, ketamine, SPRAVATO®, psychedelic medicine, electroconvulsive therapy). The core electronic health record (EHR) technology is precisely developed for interventional treatment workflows and designed to support a strong therapeutic alliance, including journaling tools and assistance with health plan reimbursement, which is a significant access hurdle for millions of patients.
Research from our platform is already helping to set new standards for mental health interventions. For example, in the largest published real-world analysis of ketamine infusion therapy for depression, we teamed up with Stanford University School of Medicine to share findings in the Journal of Affective Disorders (March 2022). We have multiple ongoing research studies leveraging our proprietary real-world data, including an even larger ketamine analysis leveraging machine learning to predict treatment outcomes.
Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists. We are backed by top investors including DFJ Growth, General Catalyst, Future Ventures, Tiger Global, and Y Combinator.
We are a series B funded Public Benefit Corporation (PBC) building something that actually moves the needle on the global mental health crisis. (See here for an article our cofounder Jimmy wrote about PBC’s.)
We are looking for a part time Customer Experience Associate to be a part of our growing CX team. This role gives you opportunity to work directly with our customers, but also own and shape the future of a specific service that Osmind offers. As CEA, you will report directly to our Customer Operations Lead and help be the face of Osmind to our customers.
Note : This is a part-time remote role. You must be available during the following working hours:
Monday-Friday, 6-10pm PT
Saturday-Sunday, 9am-5pm PT
What you'll do
What we're looking for
Nice to haves
Some candidates may see the list above and feel discouraged because they don't match all the items. Please apply anyway: there's a good chance you also have important skills we’ve missed! We are committed to diversity and building an equitable and inclusive environment for people of all backgrounds and experiences, and we're taking steps to meet that commitment. We especially encourage members of traditionally underrepresented communities to apply, including women, underrepresented people of color, LGBTQ+ people, veterans, and people with disabilities.
Osmind is a public benefit corporation and platform for clinicians and researchers advancing new life-saving mental health treatments. We recently published our first Public Benefit Report that chronicles how our team of scientists, technologists, and psychiatrists have been working to help solve the worldwide mental health crisis, advance responsible innovation and research, and help ensure robust access to care for patients of all backgrounds. Read the report here: https://www.osmind.org/pbc.
Osmind is the platform for breakthrough mental health research and treatment. Leading interventional clinicians rely on Osmind to safely administer, monitor, and analyze the use of TMS, ketamine, SPRAVATO®, psychedelic medicine, and other psychiatric medications for people living with moderate to severe mental health conditions. The core EHR technology is the first and only platform that solves specific challenges faced by these practices, capturing research-grade data while optimizing for mental health workflows and patient care journeys
Osmind works with scientists to analyze anonymized, aggregated real-world information to improve psychiatric clinical care and enable the discovery, development, and commercialization of next-generation therapeutics, diagnostics, and precision treatment approaches. Research from the Osmind platform is already helping to set new standards for mental health interventions, including recently the largest published real-world analysis of ketamine infusion therapy in collaboration with Stanford.
Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists. The company announced its $40M Series B round led by DFJ Growth in Spring 2022 and is also backed by General Catalyst, Future Ventures, Tiger Global, and Y Combinator.